Omeros (OMER) Stock: Buy, Sell, or Hold?
OMER - Omeros Corporation
$18.61
0.14 (0.76%)
▲
5d:
-7.32%
30d:
-1.33%
90d:
+79.98%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When OMER Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OMER shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: OMER shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$59.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$37.18
49.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: OMER is currently trading at $18.61, which is considered fair relative to its 30-day fair value range of $18.04 to $19.81. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.1) compared to its historical average (64.0). Remarkably, the market is currently pricing in an annual earnings decline of 38.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, OMER is in a strong uptrend. Immediate support is located at $17.82, while resistance sits at $21.24.
Market Sentiment: OMER scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.50 (+47.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OMER is in a strong uptrend. Immediate support is located at $17.82, while resistance sits at $21.24.
Market Sentiment: OMER scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.50 (+47.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$18.04 -
$19.81
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
Protect Your Profits
Holding OMER? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 47.8% below Wall St target ($27.50)
- CAUTION: 5-day price weakness (-7.3%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$18.04 -
$19.81
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$17.82
Resistance Level
$21.24
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.13
Wall Street Target
$27.50
(+47.8%)
Revenue Growth (YoY)
14.9%
Profit Margin
324.9%
Valuation Discount vs History
-38.2% cheaper
PE vs Historical
15.1 vs 64.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-38.2%
(market-implied from PE analysis)
1-Year Target
$16.75
(-10%)
2-Year Target
$15.07
(-19%)
3-Year Target
$13.57
(-27%)
3-Yr Target (if PE normalizes)
(PE: 15→64)
$57.39
(+208%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 78.3%)
$84.69
(+355%)
Base:
(SPY PE: 15.1, Growth: 78.3%)
$62.81
(+238%)
Bear:
(PE: 12.9, Growth: 78.3%)
$53.39
(+187%)
📈
Valuation based on Current Earnings
Trailing PE: 11.19 | Current EPS (TTM): $1.65
Bull Case
$15.15
(-19%)
Analyst growth -25.5%, PE expands to 12.3
Base Case
$13.77
(-26%)
Market implied -25.5%, PE stable at 11.2
Bear Case
$12.56
(-33%)
Severe decline -20.0%, PE contracts to 9.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.1 to 64.0
Stabilization Target:
$78.72
(+323.0%)
PE Expansion Potential:
+323.0%
Share & Embed Analysis
Last updated: October 03, 2026 1:11 AM ET
Data refreshes hourly during market hours. Next update: 2:11 AM
Data refreshes hourly during market hours. Next update: 2:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OMER showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 57 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 66 BUY |
Advanced OMER Option Strategies
Professional options setups generated by AI based on today's OMER price and gamma walls.
